Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
09/15/20167:26PMGLOBEXOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
Results Demonstrate XOMA 358 Mechanism-of-Action in Rare Endocrine ConditionsCompany Plans to Advance XOMA 358 to Multi-dose Phase 2b Studies BERKELEY, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, provided an update on its... More...>>
09/06/20169:00AMGLOBEXOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016
BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it will host a webcast and conference call on September 15, 2016, at 1:30 p.m. PDT (4:30 p.m. EDT), to provide an update on the ongoing XOMA 358 Phase... More...>>
08/11/20162:33PMGLOBEXOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference
BERKELEY, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the Company’s Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 17... More...>>
08/03/20164:01PMGLOBEXOMA Reports Second Quarter 2016 Achievements and Financial Results
BERKELEY, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and financial results for the second quarter ended June 30, 2016. “The second quarter of 2016 marked our full transition to a solely... More...>>
07/20/20169:00AMGLOBEXOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism
XOMA 358 previously secured Orphan Drug Designation from the FDA for the treatment of Congenital Hyperinsulinism (CHI)Phase 2 clinical studies currently enrolling patients with CHI in the United States and European Union   BERKLEY, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), a leader... More...>>
07/05/20162:06PMGLOBEXOMA to Present at the Cantor Fitzgerald Healthcare Conference
BERKELEY, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the Company’s Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Cantor... More...>>
07/05/20167:45AMPRNUSWhy Investors Love These Biotech's Stocks? - XOMA Corp., Navidea Biopharma, Radius Health, and Cara Therapeutics
Why Investors Love These Biotech's Stocks? - XOMA Corp., Navidea Biopharma, Radius Health, and Cara Therapeutics PR Newswire NEW YORK, July 5, 2016 NEW YORK, July 5, 2016 /PRNewswire/ -- The Biotech arena continues to compete with pricing pressures and economic uncertainty, but the overall performance of each operator... More...>>
06/28/20169:01AMGLOBEXOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213
BERKELEY, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its Phase 2 proof-of-concept study for XOMA 213.  XOMA 213 (formerly referred to as LFA102) is a monoclonal antibody that neutralizes... More...>>
06/02/20161:48PMGLOBEXOMA to Present at the Jefferies Global Healthcare Conference
BERKELEY, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the Company’s Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2016... More...>>
05/04/20164:01PMGLOBEXOMA Reports First Quarter 2016 Operational Achievements and Financial Results
BERKELEY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational achievements and financial results for the first quarter ended March 31, 2016. “Our efforts are squarely focused on generating the... More...>>
04/28/201611:46AMGLOBEXOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
BERKELEY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its proof-of-concept study to evaluate the safety and clinical pharmacology of a single dose of XOMA 358 in patients who experience dangerously... More...>>
04/04/20169:00AMGLOBEXOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
BERKELEY, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from XOMA 129, the lead compound in the Company’s XMetD antibody fragment (Fab) program, at the Endocrine Society’s Annual Meeting... More...>>
03/09/20167:46PMGLOBEXOMA to Present at the Cowen & Company Health Care Conference
BERKELEY, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company’s Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Cowen and Company... More...>>
03/09/20167:46PMGLOBEXOMA to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Webcast on March 9
BERKELEY, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, March 9, 2016, at 4:30 p.m. Eastern Standard Time to discuss fourth quarter and full year 2015 financial... More...>>
12/01/201510:20AMDJNNovo Nordisk Buys Xoma's Diabetes Treatment
Novo Nordisk A/S has agreed to buy the global rights to Xoma Corp.'s Type 2 diabetes treatment in a deal worth up to $295 million. The price tag includes a $5 million upfront payment to Xoma and up to $290 million in milestones. Xoma also is eligible for royalties on product sales. Shares of Xoma rose 24% in recent... More...>>
12/01/20159:52AMDJNNovo Nordisk Buys Rights to Xoma's Diabetes Treatment for $295 Million
By Chelsey Dulaney Novo Nordisk A/S has agreed to buy the global rights to Xoma Corp.'s Type 2 diabetes treatment in a deal worth up to $295 million. The price tag includes a $5 million upfront payment to Xoma and up to $290 million in milestones. Xoma also is eligible for royalties on product sales. Shares of Xoma... More...>>
12/01/20158:30AMGLOBEXOMA Announces License Agreement With Novo Nordisk for XMetA Program in Diabetes
Novo Nordisk acquires exclusive global rights to XMetA program for the treatment of diabetes XOMA retains commercialization rights for rare disease indications $5.0 million upfront payment Agreement includes up to $290.0 million in additional potential milestone payments XOMA is entitled to tiered royalties BERKELEY, Calif... More...>>
11/12/20153:00PMGLOBEXOMA to Present at Two Upcoming Investor Conferences
BERKELEY, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today members of its executive team will present at two upcoming investor conferences. The details are as follows: Jefferies Autumn 2015 Global Healthcare Conference... More...>>
11/06/201512:16PMTMFWhy XOMA Shares Are Crashing
http://www.fool.com/investing/general/2015/11/06/why-xoma-shares-are-crashing.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/05/20154:10PMGLOBEXOMA Announces the Sale of Its Manufacturing Facilities to Agenus
BERKELEY, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus Inc. (Nasdaq:AGEN). The transaction is expected... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:us D:20160929 06:46:22